Vistagen Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On August 4, 2026, Vistagen Therapeutics received notice from Nasdaq of failure to satisfy continued listing requirements (Item 3.01). The filing provides no details on specific violations, remediation plans, or timeline. This represents a critical threat to the company's public market status and ability to access capital.
Why this rating
Delisting notice is existential for a $137.7M biotech; loss of public listing status threatens capital access, valuation, and survival.
Extracted items
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.